Lucintel's latest market report analyzed that subcutaneous drug delivery device provides attractive opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy channels. The subcutaneous drug delivery device market is expected to reach $50 billion by 2030 with a CAGR of 10.5% from 2023 to 2030. In this market, pen injector is the largest segment by product, whereas retail pharmacy is largest by distribution channel.
Based on product, the
subcutaneous drug delivery device market is segmented into prefilled syringes,
pen injectors, auto-injectors, wearable injectors, and needle-free injectors.
The pen injector segment accounted for the largest share of the market in 2023
and is expected to register the highest CAGR during the forecast period, due to
its expanding usage because of its easy-to-use features, easily availability,
cost effectiveness, and high societal acceptance.
Browse in-depth TOC on
“Subcutaneous Drug Delivery Device Market”
100 – Figures/Tables
150 – Pages
The Subcutaneous Drug
Delivery Device Market is marked by the presence of several big and small
players. Some of the prominent players offering subcutaneous drug delivery
device include Gerresheimer, Medtronic, Ypsomed, Elcam Medical Group, and Novo
Nordisk.
Download sample by
clicking on subcutaneous drug delivery device market.
This unique research report will enable you
to make confident business decisions in this globally competitive marketplace. For
a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on
this link helpdesk@lucintel.com.
About Lucintel
Lucintel,
the premier global management consulting and market research firm, creates
winning strategies for growth. It offers market assessments, competitive
analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Explore Our Latest Publications
No comments:
Post a Comment